[1] |
LIU Min, CHEN Yan, LIU Wendong, WANG Haixue.
Updates and reflections on expedited reporting of safety information during drug clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
|
[2] |
XIA Xudong, LI Meixia, SUN Yang, YANG Shengya.
Processes of remote inspection of pharmacovigilance for marketing authorization holders
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
|
[3] |
LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing.
Management of individual adverse drug reaction reports
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
|
[4] |
PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu.
Exploring the significance of collecting patient reports based on international pharmacovigilance experience
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
|
[5] |
SHEN Yanjie, WU Yiqing.
Management of adverse events during clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986.
|
[6] |
LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue.
Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
|
[7] |
ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan.
Comparison standard terminology for pharmaceutical dose forms
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
|
[8] |
ZHAO Wenhua, SHU He, NI Chenming, GUO Jinmin.
Data mining and analysis of adverse drug reaction signals of fampridine sustained-release tablets based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 684-690.
|
[9] |
LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping.
Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
|
[10] |
HUO Peiqiong, ZHENG Peng, SU Zhenhao.
Pharmacovigilance in retail pharmacies for special or major diseases
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
|
[11] |
YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing.
Safety of sugammadex for reversal of neuromuscular block based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
|
[12] |
PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao.
Establishment of patient reporting scheme in the UK and its implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263.
|
[13] |
JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang.
Evaluation index system of MAH pharmacovigilance work
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
|
[14] |
WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong.
Current applications of artificial intelligence in pharmacovigilance in the USA and implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
|
[15] |
ZHENG Yi, ZHAI Yinghong, GUO Xiaojing, XU Jinfang, CHI Lijie, GUO Zhijian, CHEN Chenxin, LIANG Jizhou, WEI Lianhui, CHEN Xiao, YE Xiaofei, HE Jia.
Thyroid immune-related adverse reactions of immune checkpoint inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 92-95.
|